MY182773A - Method for indicating a presence or non-presence of aggressive prostate cancer - Google Patents
Method for indicating a presence or non-presence of aggressive prostate cancerInfo
- Publication number
- MY182773A MY182773A MYPI2015701578A MYPI2015701578A MY182773A MY 182773 A MY182773 A MY 182773A MY PI2015701578 A MYPI2015701578 A MY PI2015701578A MY PI2015701578 A MYPI2015701578 A MY PI2015701578A MY 182773 A MY182773 A MY 182773A
- Authority
- MY
- Malaysia
- Prior art keywords
- prostate cancer
- aggressive prostate
- indicating
- various forms
- present
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 2
- 230000002068 genetic effect Effects 0.000 abstract 2
- 239000000090 biomarker Substances 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000013610 patient sample Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Chemistry (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1251312 | 2012-11-20 | ||
| SE1350600 | 2013-05-16 | ||
| PCT/EP2013/074259 WO2014079865A1 (en) | 2012-11-20 | 2013-11-20 | Method for indicating a presence or non-presence of aggressive prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY182773A true MY182773A (en) | 2021-02-05 |
Family
ID=49619938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2015701578A MY182773A (en) | 2012-11-20 | 2013-11-20 | Method for indicating a presence or non-presence of aggressive prostate cancer |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10431326B2 (enExample) |
| EP (2) | EP3327146A1 (enExample) |
| JP (2) | JP2016503301A (enExample) |
| KR (1) | KR20150110477A (enExample) |
| AU (1) | AU2013349801B2 (enExample) |
| BR (1) | BR112015011359B1 (enExample) |
| CA (2) | CA3092807C (enExample) |
| DK (1) | DK2922967T3 (enExample) |
| ES (1) | ES2667326T3 (enExample) |
| IL (1) | IL238724A0 (enExample) |
| MY (1) | MY182773A (enExample) |
| RU (1) | RU2675370C2 (enExample) |
| WO (1) | WO2014079865A1 (enExample) |
| ZA (1) | ZA201503460B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101933752B1 (ko) | 2012-03-05 | 2018-12-28 | 오와이 아크틱 파트너스 에이비 | 전립선 암의 위험성 및 전립선 부피를 예측하는 방법 및 장치 |
| AU2013349721B2 (en) | 2012-11-20 | 2019-03-28 | A3P Biomedical Ab | Prognostic method for individuals with prostate cancer |
| EP4220170A3 (en) | 2014-03-11 | 2023-12-13 | Phadia AB | Method for detecting a solid tumor cancer |
| ES2964706T3 (es) | 2014-03-28 | 2024-04-09 | Opko Diagnostics Llc | Composiciones y métodos relacionados con el diagnóstico de cáncer de próstata |
| US12326453B2 (en) * | 2014-03-28 | 2025-06-10 | Opko Diagnostics, Llc | Compositions and methods for active surveillance of prostate cancer |
| HUE055020T2 (hu) | 2015-03-27 | 2021-11-29 | Opko Diagnostics Llc | Prosztata-antigén szabványok és azok felhasználása |
| US9858665B2 (en) * | 2015-04-03 | 2018-01-02 | Regents Of The University Of Minnesota | Medical imaging device rendering predictive prostate cancer visualizations using quantitative multiparametric MRI models |
| EP3287786A3 (en) * | 2015-04-29 | 2018-03-21 | Opko Diagnostics, LLC | Compositions and methods for active surveillance of prostate cancer |
| WO2017164699A1 (ko) * | 2016-03-24 | 2017-09-28 | 서울대학교병원 (분사무소) | 전립선암과 관련된 단일염기다형성 및 이를 이용한 유전 위험도 점수의 개발 |
| EP3270163B1 (en) * | 2016-07-15 | 2018-09-05 | ProteoMediX AG | Method of detecting proteins in human samples and uses of such methods |
| CN110382718A (zh) * | 2017-02-01 | 2019-10-25 | 法迪亚股份有限公司 | 用于指示具有特定特征的个体中的前列腺癌的存在或不存在的方法 |
| KR102093453B1 (ko) * | 2018-01-08 | 2020-03-25 | (주)인실리코젠 | 체형 및 대사 감수성 snp 마커 및 진단정보 제공방법 |
| CA3100137A1 (en) | 2018-01-22 | 2019-07-25 | Phadia Ab | Method for the harmonization of assay results |
| IT201800021394A1 (it) * | 2018-12-28 | 2020-06-28 | Daniela Terracciano | Metodo in vitro per la diagnosi del cancro alla prostata |
| US11633146B2 (en) | 2019-01-04 | 2023-04-25 | Regents Of The University Of Minnesota | Automated co-registration of prostate MRI data |
| US11631171B2 (en) | 2019-01-10 | 2023-04-18 | Regents Of The University Of Minnesota | Automated detection and annotation of prostate cancer on histopathology slides |
| CN109628564B (zh) * | 2019-02-25 | 2022-02-01 | 北京市理化分析测试中心 | 一种用于检测snp多态性的引物组和利用引物组检测snp多态性的方法 |
| KR102371655B1 (ko) * | 2019-02-28 | 2022-03-08 | 주식회사 프로카젠 | 각 유전 변이 정보에 개별적인 가중치를 부여한 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체 |
| KR102068667B1 (ko) * | 2019-02-28 | 2020-01-21 | 주식회사 프로카젠 | 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체 |
| KR102371654B1 (ko) * | 2019-02-28 | 2022-03-08 | 주식회사 프로카젠 | 유전 변이의 개수에 따른 예측력을 고려한 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체 |
| KR102068666B1 (ko) * | 2019-02-28 | 2020-02-11 | 주식회사 프로카젠 | 인종 별 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체 |
| IT202000029948A1 (it) * | 2020-12-04 | 2022-06-04 | Nib Biotec S R L | Metodo per la diagnosi di tumore alla prostata in pazienti in differente fascia di età |
| JP7641532B2 (ja) * | 2020-08-28 | 2025-03-07 | 国立研究開発法人理化学研究所 | 前立腺がんの検査方法 |
| GB2599198B (en) * | 2021-06-15 | 2022-12-07 | A3P Biomedical Ab | A method for determining an appropriate time interval for further diagnostic testing for prostate cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030219840A1 (en) | 2002-05-24 | 2003-11-27 | Mikolajczyk Stephen D. | Method of analyzing proenzyme forms of prostate specific antigen in serum to improve prostate cancer detection |
| FR2934698B1 (fr) * | 2008-08-01 | 2011-11-18 | Commissariat Energie Atomique | Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede. |
| CA2750062A1 (en) | 2009-01-19 | 2010-07-22 | Katrin Stedronsky | Diagnostic assays for prostate cancer using psp94 and psa biomarkers |
| WO2010093939A2 (en) | 2009-02-12 | 2010-08-19 | Dana-Farber Cancer Institute, Inc. | Predicting and treating prostate cancer |
| WO2011150515A1 (en) * | 2010-06-01 | 2011-12-08 | Universite Laval | Prognostic markers for prostate cancer recurrence |
| WO2012031207A2 (en) | 2010-09-03 | 2012-03-08 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with prostate cancer risk |
| US20120202888A1 (en) | 2010-10-08 | 2012-08-09 | The Brigham And Women's Hospital, Inc. | Biomarkers of prostate cancer and predicting mortality |
| US20120150032A1 (en) * | 2010-12-13 | 2012-06-14 | Julius Gudmundsson | Sequence Variants Associated with Prostate Specific Antigen Levels |
| US20150094221A1 (en) | 2012-05-16 | 2015-04-02 | Phadia Ab | Method for Indicating the Presence or Non-Presence of Prostate Cancer |
| AU2013349721B2 (en) | 2012-11-20 | 2019-03-28 | A3P Biomedical Ab | Prognostic method for individuals with prostate cancer |
-
2013
- 2013-11-20 AU AU2013349801A patent/AU2013349801B2/en active Active
- 2013-11-20 EP EP17210720.3A patent/EP3327146A1/en not_active Withdrawn
- 2013-11-20 EP EP13792689.5A patent/EP2922967B1/en active Active
- 2013-11-20 CA CA3092807A patent/CA3092807C/en active Active
- 2013-11-20 ES ES13792689.5T patent/ES2667326T3/es active Active
- 2013-11-20 US US14/443,970 patent/US10431326B2/en active Active
- 2013-11-20 KR KR1020157015113A patent/KR20150110477A/ko not_active Ceased
- 2013-11-20 JP JP2015542308A patent/JP2016503301A/ja active Pending
- 2013-11-20 RU RU2015124054A patent/RU2675370C2/ru active
- 2013-11-20 CA CA2891392A patent/CA2891392C/en active Active
- 2013-11-20 BR BR112015011359-1A patent/BR112015011359B1/pt not_active IP Right Cessation
- 2013-11-20 DK DK13792689.5T patent/DK2922967T3/en active
- 2013-11-20 MY MYPI2015701578A patent/MY182773A/en unknown
- 2013-11-20 WO PCT/EP2013/074259 patent/WO2014079865A1/en not_active Ceased
-
2015
- 2015-05-10 IL IL238724A patent/IL238724A0/en unknown
- 2015-05-18 ZA ZA2015/03460A patent/ZA201503460B/en unknown
-
2018
- 2018-10-04 JP JP2018189147A patent/JP2019049559A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20150317431A1 (en) | 2015-11-05 |
| CA2891392C (en) | 2020-11-03 |
| US10431326B2 (en) | 2019-10-01 |
| BR112015011359B1 (pt) | 2022-12-06 |
| ES2667326T3 (es) | 2018-05-10 |
| WO2014079865A1 (en) | 2014-05-30 |
| CA3092807A1 (en) | 2014-05-30 |
| JP2016503301A (ja) | 2016-02-04 |
| DK2922967T3 (en) | 2018-04-16 |
| CA3092807C (en) | 2024-02-27 |
| KR20150110477A (ko) | 2015-10-02 |
| ZA201503460B (en) | 2018-11-28 |
| EP3327146A1 (en) | 2018-05-30 |
| EP2922967B1 (en) | 2018-01-03 |
| AU2013349801B2 (en) | 2019-03-07 |
| RU2675370C2 (ru) | 2018-12-19 |
| HK1215594A1 (en) | 2016-09-02 |
| BR112015011359A2 (pt) | 2017-07-11 |
| CN105051206A (zh) | 2015-11-11 |
| JP2019049559A (ja) | 2019-03-28 |
| IL238724A0 (en) | 2015-06-30 |
| RU2015124054A (ru) | 2017-01-10 |
| AU2013349801A1 (en) | 2015-05-28 |
| BR112015011359A8 (pt) | 2019-10-01 |
| EP2922967A1 (en) | 2015-09-30 |
| CA2891392A1 (en) | 2014-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY182773A (en) | Method for indicating a presence or non-presence of aggressive prostate cancer | |
| WO2013172779A3 (en) | Method for indicating the presence or non-presence of prostate cancer | |
| MX368513B (es) | Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón. | |
| HK1213946A1 (zh) | 用於使用c-maf对前列腺癌转移进行诊断、预後和治疗的方法 | |
| WO2012045905A3 (es) | Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama | |
| MX2020001156A (es) | Metodo para el pronostico y tratamiento de metastasis de cancer. | |
| EA201590027A1 (ru) | Способы детекции заболеваний или состояний | |
| PH12018550037A1 (en) | Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof | |
| IN2013CN01129A (enExample) | ||
| MY195999A (en) | Molecular Detection/Diagnosis Reagent for Tumor | |
| MX356986B (es) | Metodo para detectar aductos de nucleosomas. | |
| EP4604127A3 (en) | Methods and processes for non-invasive assessment of genetic variations | |
| WO2013025952A3 (en) | Methods and compositions for the treatment and diagnosis of breast cancer | |
| TR201907389T4 (tr) | Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem. | |
| MX347895B (es) | Dispositivo y método para obtener y procesar lecturas de medición de un ser vivo. | |
| MX2015011373A (es) | Metodo para el diagnostico, pronostico y tratamiento de la metastasis de un cancer. | |
| IN2012DN04944A (enExample) | ||
| EA201700123A1 (ru) | Способ прогнозирования варианта лекарственного препарата для лечения депрессии | |
| WO2019094780A3 (en) | Non-coding rna for detection of cancer | |
| MY195045A (en) | Specific Biomarker Set For Non-Invasive Diagnosis of Liver Cancer | |
| MX357429B (es) | Predictores para el tratamiento del cáncer. | |
| MX359376B (es) | Metodo y kit para la determinacion de cobre libre en suero. | |
| EP2584045A4 (en) | METHOD FOR DETECTING COLORECTAL CANCER | |
| CA2977439C (en) | MICRORNA-BASED METHOD FOR EVALUATING THE PROGNOSIS OF A PATIENT WITH PROSTATE CANCER | |
| PH12015500388A1 (en) | Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells |